Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Historical Valuation Ratios (Summary)

Merck & Co. Inc., historical price multiples (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Price to earnings (P/E)
Price to operating profit (P/OP)
Price to sales (P/S)
Price to book value (P/BV)

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


Price to Earnings (P/E) Ratio
The P/E ratio exhibited notable volatility over the observed periods. Starting at 28 in early 2021, the ratio rose to peaks of 34.23 in mid-2021 before declining sharply to values around 14-16 by the end of 2021 and early 2022. A gradual increase followed, reaching an extraordinary peak of 893.99 at the end of 2023, which likely indicates an exceptional event or anomaly during that quarter. Subsequently, the P/E ratio showed a steep correction, declining to approximately 20 by mid-2024 and further decreasing to levels near 11 by late 2025. This pattern reflects significant fluctuations in investor sentiment or earnings performance, with a general downward trend in the ratio from 2024 onwards.
Price to Operating Profit (P/OP) Ratio
The P/OP ratio mirrors the volatility witnessed in the P/E ratio. It started around 30 in early 2021, dropping sharply to below 15 by the end of 2021 and early 2022. The ratio later climbed to a peak of 138.56 in late 2023, echoing the extraordinary spike seen in the P/E ratio. After this peak, the ratio declined significantly, stabilizing near single-digit values (around 9.67) by the third quarter of 2025. This trend suggests fluctuating operating profitability relative to market valuation, with the market correcting itself after an unusual price elevation.
Price to Sales (P/S) Ratio
The P/S ratio displayed relatively mild fluctuations compared to earnings-based multiples. It maintained a range between approximately 3.17 and 5.43 throughout the period. Starting at 4.23 in early 2021, the ratio remained steady with minor oscillations, peaking at 5.43 in late 2023. Thereafter, it gradually decreased to values around 3.26 by late 2025. This implies more consistent sales performance relative to market pricing without extreme volatility seen in earnings multiples.
Price to Book Value (P/BV) Ratio
The P/BV ratio started relatively high at 7.3 in early 2021 and showed a gradual declining trend over time, with some short-term increases. Following a dip below 5.0 during mid-2025, the ratio had a notable spike to 8.68 at the end of 2023, coinciding with peaks in other valuation metrics. It then trended downwards to about 4.04 by late 2025. The overall decrease implies a reduction in market valuation relative to book value, potentially reflecting changes in asset base valuation or investor perceptions.

Price to Earnings (P/E)

Merck & Co. Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
No. shares of common stock outstanding1
Selected Financial Data (US$)
Net income (loss) attributable to Merck & Co., Inc. (in millions)
Earnings per share (EPS)2
Share price1, 3
Valuation Ratio
P/E ratio4
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2025 Calculation
EPS = (Net income (loss) attributable to Merck & Co., Inc.Q3 2025 + Net income (loss) attributable to Merck & Co., Inc.Q2 2025 + Net income (loss) attributable to Merck & Co., Inc.Q1 2025 + Net income (loss) attributable to Merck & Co., Inc.Q4 2024) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q3 2025 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =

5 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals notable fluctuations and trends in share price, earnings per share (EPS), and price-to-earnings (P/E) ratio over the examined periods.

Share Price
The share price exhibited an overall upward trajectory from early 2021 to late 2023, increasing from $77.7 to a peak of $128.84 by December 2023. However, this was followed by a consistent decline through 2024 and into 2025, with the price falling to $80.79 by mid-2025 before a slight recovery to $84.39 by September 2025. This pattern suggests a period of growth followed by market corrections or external pressures impacting investor sentiment.
Earnings Per Share (EPS)
EPS showed significant variability over the quarters. Starting at $2.78 in March 2021, it climbed impressively to a high of $6.54 by June 2022, signaling enhanced profitability. Following this, EPS dipped sharply in late 2023, hitting a notably low of $0.14 in December 2023. This low was short-lived as EPS rebounded strongly in 2024 and into 2025, reaching $7.67 by September 2025. The volatility in EPS indicates possible business cycle fluctuations, exceptional items, or other operational impacts affecting profitability within specific quarters.
Price-to-Earnings (P/E) Ratio
The P/E ratio mirrored the changes observed in EPS and share price, but with heightened sensitivity. Initially fluctuating between 13 and 34 from 2021 to early 2023, it spiked dramatically to an extreme high of 893.99 in December 2023. This anomalous value aligns with the very low EPS at that time, reflecting the inverse relationship between EPS and P/E when earnings decline sharply. Subsequently, the P/E ratio normalized towards mid-2024 and maintained more moderate levels ranging from approximately 11 to 21 through 2025, consistent with recovering EPS and stabilizing share price.

In summary, the data reflects a period marked by growth in both share price and earnings up to mid-2022, followed by a notable period of earnings volatility and price correction through 2023. The anomalous P/E spike corresponds directly to a sharp dip in earnings, after which financial metrics stabilized and showed recovery trends into 2025. Such dynamics suggest underlying shifts in operational performance, market conditions, or external factors impacting quarterly financial results during the observed timeframe.


Price to Operating Profit (P/OP)

Merck & Co. Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
No. shares of common stock outstanding1
Selected Financial Data (US$)
Operating income (loss) (in millions)
Operating profit per share2
Share price1, 3
Valuation Ratio
P/OP ratio4
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2025 Calculation
Operating profit per share = (Operating income (loss)Q3 2025 + Operating income (loss)Q2 2025 + Operating income (loss)Q1 2025 + Operating income (loss)Q4 2024) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q3 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =

5 Click competitor name to see calculations.


The financial data indicates several notable trends in the share price, operating profit per share (OP), and the price-to-operating profit (P/OP) ratio over the reported periods.

Share Price
The share price generally exhibited a rising trend from the first quarter of 2021 through the first quarter of 2023, increasing from $77.7 to a peak of $128.84 in December 2023. Subsequently, a decline occurred, with the share price falling to $80.79 by June 2025. This pattern suggests a period of growth followed by a correction or market adjustment.
Operating Profit per Share (OP)
Operating profit per share showed significant variability. It started at $2.58 in March 2021, peaked around $7.46 in June 2022, then fluctuated with a sharp dip to $0.93 in December 2023. After that, OP recovered robustly, reaching $8.73 by September 2025. This indicates periods of strong operational performance interspersed with temporary setbacks, followed by a strong recovery towards the end of the timeline.
Price-to-Operating Profit (P/OP) Ratio
The P/OP ratio reflected significant volatility and inverse movements relative to operating profit per share. Starting high at 30.14 in March 2021, it declined to a low point around 10.37 in June 2025. Between mid-2023 and early 2024, the ratio spiked dramatically, reaching an extreme of 138.56 in December 2023, coinciding with the nadir in operating profit. This suggests periods where market valuation was disproportionately high relative to earnings, potentially due to transitory earnings dips or market speculation.
Interrelations and Insights
The share price movements generally mirrored trends in operating profit per share but with some lag and occasional divergence. The sharp increase in the P/OP ratio towards late 2023 highlights a disconnect between the company's earnings and its market valuation, which was corrected in subsequent quarters. The return to lower P/OP ratios and recovering operating profits towards 2025 may indicate restored confidence in underlying operational performance.

Price to Sales (P/S)

Merck & Co. Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
No. shares of common stock outstanding1
Selected Financial Data (US$)
Sales (in millions)
Sales per share2
Share price1, 3
Valuation Ratio
P/S ratio4
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2025 Calculation
Sales per share = (SalesQ3 2025 + SalesQ2 2025 + SalesQ1 2025 + SalesQ4 2024) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q3 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =

5 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals a number of notable trends across share price, sales per share, and price-to-sales (P/S) ratio over multiple periods.

Share Price
The share price exhibits considerable volatility over the examined timeframe. It begins at approximately $77.70, followed by fluctuating intervals including a notable peak near $128.84 and subsequently demonstrating a downward trajectory toward the end of the period, with prices descending to roughly $80.79 before a slight recovery observed in the most recent data point. The overall pattern indicates periods of growth interspersed with corrections, suggesting market responsiveness to various external or company-specific factors.
Sales per Share
Sales per share display a consistent upward trend across the quarters. Starting at $18.39, the value steadily increases with only marginal fluctuations, reaching nearly $25.88 in the latest period. This progression signifies sustained revenue growth on a per-share basis, reflecting enhanced operational performance or sales volume expansion that contributes positively to shareholder value.
Price-to-Sales (P/S) Ratio
The P/S ratio follows a pattern reflecting both share price movements and sales growth. Initially around 4.23, the ratio fluctuates, reaching a high mark near 5.43, indicating periods where the share price outpaced sales growth appreciably. However, toward the latter part of the dataset, the P/S ratio declines to approximately 3.26, which could imply a relative market repricing or moderation in investor expectations despite the rising sales per share. This decrease in P/S ratio towards the end, coinciding with declining share prices, suggests a valuation adjustment or a shift in market sentiment.

In summary, the data portrays a company that maintains steady sales growth per share, but exhibits variable share prices and fluctuating market valuations as reflected in the P/S ratio. The observed share price peaks and subsequent corrections, alongside a relatively stable increase in sales, may point to external market influences or strategic developments impacting investor perception over time.


Price to Book Value (P/BV)

Merck & Co. Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
No. shares of common stock outstanding1
Selected Financial Data (US$)
Total Merck & Co., Inc. stockholders’ equity (in millions)
Book value per share (BVPS)2
Share price1, 3
Valuation Ratio
P/BV ratio4
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2025 Calculation
BVPS = Total Merck & Co., Inc. stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q3 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =

5 Click competitor name to see calculations.


The analyzed financial data reflects notable trends and fluctuations in the share price, book value per share (BVPS), and price-to-book value ratio (P/BV) over multiple quarterly periods.

Share Price
The share price exhibited an upward trend from the first quarter of 2021 through the end of 2024, increasing from $77.70 to a peak of $128.84 in December 2023. After reaching this high, the price demonstrated volatility with a general downward movement throughout 2024 and into 2025, falling to $84.39 by September 2025. This suggests a period of robust investor confidence followed by some market corrections or external factors affecting valuation.
Book Value Per Share (BVPS)
BVPS showed a steady and consistent increase across the entire period, rising from $10.64 in March 2021 to $20.89 by September 2025. This steady growth implies ongoing accumulation of equity and retention of earnings, reflecting sound internal value creation and capital growth within the company.
Price-to-Book Value Ratio (P/BV)
The P/BV ratio experienced fluctuations that partially mirror the trends in share price relative to BVPS changes. Initially, the ratio decreased from 7.3 to around 5.0-6.0 in 2021 and early 2022, indicating that the share price growth was more modest compared to the increases in book value per share. Subsequently, the P/BV ratio climbed significantly, peaking at 8.68 by December 2023, highlighting a surge in market valuation relative to book value. However, post this peak, the ratio saw a steady decline down to approximately 4.04 by September 2025, reflecting a market valuation contraction relative to the company's book value, consistent with the decrease in the share price.

Overall, the data shows a company with growing intrinsic value as evidenced by the steady increase in book value per share, tempered by significant fluctuations in market valuation as shown in the share price and P/BV ratio trends. The notable peak in market valuation toward the end of 2023 followed by a marked decline in 2024 and 2025 suggests changing investor sentiment or external market conditions impacting the equity price despite ongoing fundamental growth.